Interleukin-2 therapy in relapsed acute myelogenous leukemia

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Meloni, Giovanna ^a   Vignetti, Marco ^a   Pogliani, Enrico ^a   Invernizzi, Rosangela ^a   Allione, Bernardino ^a   Mirto, Salvatore ^a   Sica, Simona ^a   Leoni, Franco ^a   Selleri, Carmine ^a   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myelogenous leukemia; Immunotherapy; Interleukin 2

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0031423808     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Osterwalder B. Clinical studies with interleukin-2: an overview. In: Mertelsmann R, ed. Lymphohematopoietic Growth Factors in Cancer Therapy, Vol 2: Monographs of European School of Oncology. Berlin: Springer-Verlag, 1992:57-86.
2. Adler A, Chervenick PA, Whiteside TL et al. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: feasibility of LAK generation in adult patients with active disease and in remission [part 1]. Blood 71:709-716.
3. Fierro MT, Xin-Sheng L, Lusso P et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988;2:50-54.
4. Lista P, Fierro MT, Xin-Sheng L et al. Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells. Eur J Haematol 1989;42:425-430.
5. Foa R, Caretto P, Fierro MT et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol 1990;75:34-40.
6. MacDonald D, Jiang YZ, Swirsky D et al. Acute myeloid leukemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br J Haematol 1991;77: 43-49.
7. Foa R, Fierro MT, Tosti S et al. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma 1990;1:113-117.
8. Foa R, Meloni G, Tosti S et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991;77:491-496.
9. Maraninchi D, Blaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78:2182-2187.
10. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994;84:2158-2163.
11. Meloni G, Vignetti M, Andrizzi C et al. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma 1996;21:429-435.
12. Amadori S, Arcese W, Isacchi G et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991;9:1210-1214.
13. Vignetti M, Orsini E, Petti MC et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996;7:933-938.
14. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 1993;11:1817-1825.
15. Mandelli F, Vignetti M, Tosti S et al. Interleukin 2 treatment in acute myelogenous leukemia. Stem Cells 1993;11:263-268.
16. Fefer A, Benyunes MC, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993;20:41-45.
17. Klingemann HG, Eaves CJ, Barnett MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994;14: 389-396.
18. Lim SH, Newland AC, Kelsey S et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia: a phase II study. Cancer Immunol Immunother 1992; 34:337-342.
19. Meloni G, Foa R, Tosti S et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 1992;6:780-785.